NIZORAL (ketoconazole) by Johnson & Johnson is cytochrome p450 3a4 inhibitors [moa]. Approved for azole antifungal [epc].
Drug data last refreshed 2w ago
Cytochrome P450 3A4 Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
Oral Calcitriol With Ketoconazole in CRPC
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis
Worked on NIZORAL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.